Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in Chronic Hand Eczema
2023-504298-19-00Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand dermatitis (CHE) comparing Deucravacitinib arm with Placebo arm (2 arms). Primary endpoint: Therapeutic efficacy (primary endpoint). Started Mar 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on 2023-504298-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504298-19-00.